The 5 analysts offering 12-month price forecasts for Checkpoint Therapeutics Inc have a median target of 17.00, with a high estimate of 20.00 and a low estimate of 8.00. The median estimate represents a +413.60% increase from the last price of 3.31.
The current consensus among 5 polled investment analysts is to Buy stock in Checkpoint Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.14
Reporting Date Nov 11
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.